Netia Medical Technologies
Netia Medical Technologies specializes in innovative RNAi drug design platforms, enabling carrier-free RNAi drug delivery for therapeutic applications. Their mission is to develop advanced drug design solutions that target various diseases, including age-related and multiorgan disorders, with a focus on broad tissue distribution and targeting lncRNAs for cancer treatment.
Industries
Nr. of Employees
small (1-50)
Products
Single-strand RNAi drug-design platform
A drug-design platform producing guide-strand-only and sequential single-strand RNAi therapeutics that enable carrier-free systemic delivery, high target knockdown, lncRNA targeting, splice modulation, and local dosing to protected sites.
Single-strand RNAi drug-design platform
A drug-design platform producing guide-strand-only and sequential single-strand RNAi therapeutics that enable carrier-free systemic delivery, high target knockdown, lncRNA targeting, splice modulation, and local dosing to protected sites.
Services
Discussion and negotiation for acquiring or licensing patent rights covering RNAi drug-design platforms.
Discussion and negotiation for acquiring or licensing patent rights covering RNAi drug-design platforms.
Expertise Areas
- RNA interference therapeutic design
- Oligonucleotide medicinal chemistry
- Systemic and local oligonucleotide delivery
- lncRNA-targeting strategies
Key Technologies
- Single-stranded RNAi therapeutics
- Sequential RNAi (seqRNAi) delivery
- 5'-terminal nucleotide phosphorylation strategies
- 2'-O-methyl nucleotide modification
News & Updates
Netia Medical Technologies owns a U.S. patent (US11359201B2) for RNAi drug design, with claims consistent across Europe, Australia, and Canada.
Netia Medical Technologies owns a U.S. patent (US11359201B2) for RNAi drug design, with claims consistent across Europe, Australia, and Canada.